PET-Adapted Salvage Therapy Achieves Negativity in Hodgkin Lymphoma

the Cancer Therapy Advisor take:

According to a new study published in the journal The Lancet Oncology, researchers have found that PET-adapted sequential salvage therapy with brentuximab followed by augmented ifosfamide, carboplatin, and etoposide (augICE) could optimize the chance of cure after high-dose therapy and autologous stem-cell transplant (HDT/ASCT) in patients with relapsed and refractory Hodgkin lymphoma.

For this open-label, single-center, phase 2 study, researchers enrolled 46 patients with relapsed or refractory Hodgkin lymphoma who had failed one previous doxorubicin-containing regimen. Patients received brentuximab vedotin 1.2mg/kg IV on days 1, 8, and 15 for two 28-day cycles, followed by a PET scan.

Patients who achieved a Deauville score of 1 or 2 proceeded directly to HDT/ASCT, while those with PET abnormalities received two cycles of augICE before consideration for HDT/ASCT. Results showed that 69% of the 32 evaluable patients who received augICE were PET-negative in addition to the 12 patients who were PET-negative after brentuximab treatment. All 44 patients who completed the treatment protocol proceeded to received HDT/ASCT.

The results demonstrate that PET-adapted sequential salvage therapy with brentuximab vedotin followed by augICE resulted in a high proportion of patients achieving PET-negativity.